RxDoctor Payments Data

Ransky Allonce, MD

General Practice · Margate, FLNPI 1770991010

Payments from drug & device makers

$549in general payments, 2019–2025

Across 24 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$191
  • AstraZeneca$142
  • Lilly USA, LLC$49
  • Boehringer Ingelheim$38
  • Johnson & Johnson$36
  • Exact Sciences$31
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$191
AstraZeneca8$142
Lilly USA, LLC3$49
Boehringer Ingelheim2$38
Johnson & Johnson2$36
Exact Sciences1$31
Amgen1$24
Gilead1$23
Circassia Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$549 in reported general payments places this provider in the 65th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$23,458
Medicare patients
64
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$123,513
JardianceEmpagliflozin76$113,289
EliquisApixaban87$107,730
JanuviaSitagliptin Phosphate61$95,095
FarxigaDapagliflozin Propanediol58$63,530
TrulicityDulaglutide49$62,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,742
EntrestoSacubitril/Valsartan16$22,516
Tresiba Flextouch U-100Insulin Degludec23$18,112
XareltoRivaroxaban12$15,940
TradjentaLinagliptin12$15,642
JanumetSitagliptin Phos/Metformin Hcl11$15,520
VascepaIcosapent Ethyl21$12,896
Lantus SolostarInsulin Glargine,hum.Rec.Anlog106$11,131
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$10,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$38$128,93188 claims
Novo NordiskOzempic$191$123,51384 claims
AstraZenecaFarxiga$142$63,53058 claims
Lilly USA, LLCTrulicity$49$62,07149 claims
Johnson & JohnsonXarelto$36$15,94012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,901 general practice providers in Florida.

Other general practice in Margate

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →